Skip to main content
PLOS One logoLink to PLOS One
. 2026 Feb 23;21(2):e0343413. doi: 10.1371/journal.pone.0343413

Investigating traditional and novel predictors of a single versus multiple fragility fractures in a large observational cohort

Hamzah Amin 1,*, Muhammed Aqib Khan 1, Marwan Bukhari 1,2
Editor: Gaetano Paride Arcidiacono3
PMCID: PMC12928489  PMID: 41729942

Abstract

Background

Osteoporosis is a systemic skeletal disease characterised by reduced bone mass and a distortion of bone microarchitecture. It is clinically problematic as it leads to fragility fractures which confers excess morbidity and mortality on patients. Up to 32% of individuals will experience recurrent fragility fractures within two years of an initial fracture, yet existing risk models focus on the risk of having a single fragility fracture at a time. We aim to identify predictors of multiple fragility fractures to help improve risk stratification.

Methods

43,801 patients referred for their first DXA scan in the northwest of England between June 2004 and February 2024 were analysed. Participants underwent lumbar spine and femoral scans to assess bone density and regional body composition. A generalized additive model reporting odds ratios was used to compare risk factors for a single versus multiple fragility fractures.

Results

Of the referred population, 14,212 (32.4%) had a single fragility fracture and 3,731 (8.5%) had multiple. Female gender was associated with lower odds of multiple fractures (OR 0.88, 95% CI: 0.79–0.99), while increased odds were linked to family history of fractures (OR 1.22, 95% CI: 1.11, 1.35), secondary osteoporosis (OR 1.15, 95% CI: 1.05, 1.26), rheumatoid arthritis (OR = 1.29, 95% CI: 1.08, 1.53), glucocorticoid therapy (OR = 1.18, 95% CI: 1.00, 1.39), smoking (OR 1.27, 95% CI: 1.12, 1.45) and falls risk (OR 2.02, 95% CI: 1.54, 2.63). The combination of falls risk and alcohol consumption increased multiple fracture odds (OR 7.62, 95% CI: 2.77, 20.94). Left femoral T-score and body fat percentage showed significant non-linear effects (both p < 0.001).

Conclusion

Multiple fragility fractures were associated with many traditional risk factors. We also identified a novel link between falls risk and alcohol consumption, as well as the significant associations with body composition.

Introduction

Osteoporosis (OP) is a systemic skeletal disease characterised by reduced bone density and microarchitectural distortion of bone [1,2]. Clinically bone density is derived via a dual-energy X-ray absorptiometry (DXA) scan at the lumbar spine and bilateral femurs [3] where the value is compared to a young healthy adult population deriving a T-score. With regards to bone microarchitecture this is derived using advanced algorithms such as the trabecular bone score which analyse lumbar spine DXA scans [4]. OP is a leading cause of fragility fractures which can be defined as fractures resulting in low impact trauma which would not ordinarily result in fracture, including falls from standing height and are associated with increased morbidity and mortality [5,6]. The cost of OP to the United Kingdom’s National Health Service is estimated at £4.6 billion, with this figure projected to rise as the population ages [7]. An estimated 20–32% of individuals with a fragility fracture will experience additional fractures within two years of the first fragility fracture, highlighting the importance of identifying patients who will go on to experience multiple fragility fractures [8].

There is a lack of studies specifically examining clinical risk factors for multiple fragility fractures. A notable study by Charles et al. [9] identified several clinical risk factors associated with increased odds of multiple fragility fractures at any site, including age, prior fracture history, history of falls, total hip bone mineral density, spine bone mineral density, and rheumatoid arthritis [9]. In individuals with multiple major osteoporotic fractures, defined as fractures of the femoral neck, vertebrae, proximal humerus, or wrist, the factors associated with increased odds included age, prior fracture history, parental history of hip fracture, total hip bone mineral density, and rheumatoid arthritis [9]. The study also evaluated central fractures, which included fractures of the femoral neck, vertebrae, proximal humerus, pelvis, ribs, scapula, clavicle, or sternum. Predictors of two or more central fractures included age, previous fragility fracture, bone mineral density at the total hip and spine, and higher body mass index, all of which were associated with increased odds of fracture [9]. These findings suggest that while many clinical risk factors are common across fracture types, certain predictors such as body mass index may be site-specific, underscoring the need for tailored risk assessment models in individuals with multiple fragility fractures.

Recently, newer models, such as FRAXplus, have incorporated additional risk factors to update the conventional fracture risk assessments [10]. One of these predictors is the recency of previous osteoporotic fragility fractures, with substantial research suggesting that a prior fragility fracture increases the risk of subsequent fractures [11]. However, it could be argued that identifying individuals at high risk of multiple fragility fractures before any fracture occurs may offer greater clinical value as early identification would enable timely initiation of both pharmacological and lifestyle interventions, potentially preventing a cascade of fractures. Nevertheless, before predictive models can be applied to distinguish between the risk of a single fracture and multiple fractures prior to any fracture, further research is needed to strengthen the evidence base for predictors specific to multiple fragility fractures.

Aims

The aim of this study is to investigate the predictors of multiple fragility fractures, evaluating both traditional and novel risk factors, including body composition measurements.

Methods

Data collection

43,801 patients were referred from both primary and secondary to our regional NHS DXA clinic for their first DXA scan between June 2004 and February 2024 in northwest England with data accessed on the 13/03/2024 for research purposes. At the time of each scan, trained scanning technicians conducted a structured clinical history, during which patients were asked about the presence of various clinical risk factors for fragility fractures. This information was entered by the technician into a standardised electronic questionnaire integrated within the scanning software, ensuring consistency in data collection.

The questionnaire captured demographic data, including age, as well as clinical risk factors such as family history of fractures, smoking status, current glucocorticoid therapy (defined as ≥5 mg/day of prednisolone or equivalent for ≥3 months), rheumatoid arthritis, excessive alcohol intake (>3 units/day), and known causes of secondary osteoporosis. Secondary osteoporosis was coded for individuals with conditions including polymyalgia rheumatica, coeliac disease, aromatase inhibitor use, amenorrhea, ankylosing spondylitis, anorexia (current or prior), anticonvulsant use (current or prior), breast cancer (current or prior), Depo-Provera use (current or prior), untreated early menopause, hyperparathyroidism (current or prior), hyperthyroidism (current or prior), hypogonadism, inflammatory bowel disease, malabsorption, psoriatic arthritis, systemic lupus erythematosus, and vitamin D deficiency. Data was not available on patients on antiresorptive therapy.

Additionally, patients were asked to self-report any fragility fractures that had occurred within the preceding two years, which was also included in the questionnaire. Fragility fractures were defined as those resulting from a fall from standing height or less, or due to low-impact trauma. All questionnaire responses were cross-checked against patients’ medical records to ensure data accuracy and robustness.

Bone density measurement

The GE Lunar Prodigy system was used for DXA scans between 2004 and 2019, after which the GE Lunar iDXA system was introduced and remains in use. To ensure methodological consistency between devices, phantom scans were conducted at the time of the machine upgrade to validate the use of both machines data in our analysis and in conjunction with ISCD 2019 guidelines [3]. Weekly quality control checks are also performed using phantom scans to maintain measurement accuracy on the DXA scanners [3]. The majority of patients underwent bilateral femoral and lumbar spine scans, with a small subset receiving wrist or isolated femoral scans based where clinically appropriate. Femoral scans included the head, neck, Ward’s triangle and the proximal shaft, while lumbar spine scans encompassed the L1 to L4 vertebrae. All scans followed ISCD-recommended patient positioning protocols to optimise image clarity, and exclusion criteria were applied where appropriate as per ISCD guidelines [3], though the reason for exclusion was not explicitly mentioned in the dataset and hence is treated as missing data in our statistical analysis.

Body composition measurement

Body composition was first assessed by calculating the patients BMI and was conducted by the technician at each appointment. Additionally, DXA scanners can also calculate fat mass and lean mass locally at the time of bone scan, but this data is not reported on the automatically generated bone density reports. Rather this data is stored in the machines database but can be extracted for analysis. Previous studies have outlined the methodology for these measurements [12]. Lean mass and fat mass data from the lumbar spine left and right femoral regions were used to calculate a partial body fat percentage (PBF%). This calculation was based on the sum of fat mass at the spine and bilateral femoral regions, divided by the total fat and lean mass at these sites and multiplied by 100. While this variable has not been clinically validated, previous studies have demonstrated methodological agreement and a strong correlation between regional body composition and total body fat measurements hence the use in this present study [13,14].

Ethics statement

Ethical approval for pseudonymized data extraction in the absence of informed consent was granted by the Northwest Preston NHS Research Ethics Committee (project number 21/NW/0309). The need for informed consent was waived by the ethics committee. Our data did not include any minors.

Statistical analysis

All patients who had one or more fragility fractures were included in the statistical analysis. The analysis was conducted using RStudio, with the following R packages: tidyverse, MGCV, performance, and sjplot.

Demographic variables were initially compared between the two groups: patients who had a single fragility fracture and those who had multiple fragility fractures. Patients with one fragility fractures were coded as zero, while those with two or more fragility fractures were coded as one. To compare continuous variables, we used the Student’s t-test for normally distributed data, and the Mann-Whitney U test was employed for non-normally distributed variables. For categorical variables, the chi-square test was applied to assess differences between groups.

In the primary analysis, we used a generalized additive model (GAM) with a binomial distribution and a logit link function to examine predictors of a single vs multiple fragility fractures. Categorical variables were reported as odds ratios, while continuous variables were fitted using regression splines and reported using marginal effects plot. The GAM automatically selects the optimal smoothing term for continuous variables ensuring we did not under/overfit our data. Variable selection was guided by existing literature and clinical knowledge, rather than automated procedures, to ensure that the most relevant factors were included.

Our model included continuous variables such as age, left femoral T-score, BMI, and PBF%. Categorical variables included rheumatoid arthritis, family history of previous fractures, glucocorticoid therapy, smoking status, excessive alcohol use, fall risk, recurrent falls and secondary osteoporosis. The reference group for these binary variables was the absence of the risk factor. We also included an interaction effect between fall risk/recurrent falls and excessive alcohol use given research suggesting that excessive alcohol consumption may increase both fall risk and the likelihood of recurrent falls [15]. In the context of our interaction effects the reference groups was no for both variables, e.g., falls risk ‘no’ and excessive alcohol consumption ‘no’.

Results

Baseline demographics

43,801 patients were referred for their first DXA scan between June 2004 and February 2024. This included 36,480 female and 7,321 male patients. The median age was 66.8 (IQR: 57.6–75.2) years. The median BMI was 26.4 (IQR: 23.2–30.2). 43,801 patients reported 18,037 fractures. Of these fractures, 14,212 (78.7%) patients reported only a single fracture and 3,730 (20.7%) reported 2 or more fragility fractures.

Demographic and clinical characteristics were compared between patients reporting a single fragility fracture (n = 14,212; 79.2%) and those reporting two or more fractures (n = 3,730; 20.8%). There was no significant difference in age or BMI between the groups. However, the multiple fracture group had a slightly lower proportion of female patients, and a higher proportion of male patients compared to the single fracture group (p = 0.033). This group also had a marginally higher PBF%, which was statistically significant. Additionally, they were more likely to be on corticosteroid therapy, have rheumatoid arthritis, consume excessive alcohol, report a family history of fragility fractures, and have a secondary cause of osteoporosis (all p < 0.05). As expected, they also had significantly lower left femoral T-scores (p < 0.001). Full results are presented in Table 1.

Table 1. Baseline demographics compared between those reporting 1 vs Multiple fragility fractures.

Single Fragility Fracture

(n = 14,212, 79.2%)
Multiple Fragility Fracture (n = 3,730, 20.8%) P
Demographics:
Age (years) 67 (58, 75) 67 (58, 75) 0.500
Gender 0.033
 Male 2,256 (16%) 646 (17%)
 Female 11,956 (84%) 3,084 (83%)
Body Mass Index (kg/m2) 26.3 (23.3, 30.1) 26.3 (23.1, 30.1) 0.400
Lifestyle factors:
Alcohol use (>3 units per day) 368 (2.6%) 147 (3.9%) <0.001
Current smoker 1,371 (9.6%) 433 (12%) <0.001
Medical History:
Glucocorticoid use 846 (6.0%) 271 (7.3%) 0.003
Rheumatoid arthritis 738 (5.2%) 247 (6.6%) <0.001
Falls risk 232 (1.6%) 131 (3.5%) <0.001
Recurrent falls 159 (1.1%) 92 (2.5%) <0.001
Family history of a fragility fracture 738 (5.2%) 247 (6.6%) <0.001
Secondary cause of osteoporosis 4,423 (31%) 1,282 (34%) <0.001
DXA Outcomes:
Total Left femoral T-score −1.30 (−2.09, −0.46) −1.48 (−2.23, −0.70) <0.001
PBF% 31 (26, 36) 32 (27, 37) <0.001

Data presented as n (%) for binary variable and mean (SD), median (IQR) for continuous variables. Students T-test used for continuous variables and Pearsons chi-squared used for categorical outcomes.

We also assessed whether there were differences in risk factors between male and female patients reporting multiple fragility fractures. Male patients were older than female patients (median age: 70 [IQR: 61–77] vs. 66 [IQR: 58–75] years; p < 0.001) and had a slightly higher BMI (27.0 [IQR: 24.1–29.8] vs. 26.1 [IQR: 22.9–30.3] kg/m2; p = 0.007). No other risk factors showed statistically significant differences between males and females reporting multiple fragility fractures.

Primary analysis

In our primary analysis, we found that females had decreased odds of experiencing multiple fragility fractures compared to males, with an odds ratio (OR) of 0.88 (95% CI: 0.79–0.99; p = 0.029). A family history of fragility fractures was associated with increased odds (OR = 1.22, 95% CI: 1.11–1.35; p < 0.001), as was a diagnosis of rheumatoid arthritis (OR = 1.29, 95% CI: 1.08–1.53; p = 0.004). Glucocorticoid therapy was also significantly associated with higher odds of multiple fragility fractures (OR = 1.18, 95% CI: 1.00–1.39; p = 0.049), as was the presence of a secondary cause of osteoporosis (OR = 1.15, 95% CI: 1.05–1.26; p = 0.002). All results were statistically significant and are presented in Table 2.

Table 2. Odds Ratios for the predictors in our GAM looking at predictors of multiple fragility fractures.

Risk factor OR 95% Cl p-value
Gender
Female (reference male) 0.88 0.79, 0.99 0.029
Family History of Fracture 1.22 1.11, 1.35 <0.001
Rheumatoid Arthritis 1.29 1.08, 1.53 0.004
Glucocorticoid therapy 1.18 1.00, 1.39 0.049
Excess alcohol consumption 0.98 0.83, 1.14 0.800
Current Smoker 1.27 1.12, 1.45 <0.001
Secondary cause of osteoporosis 1.15 1.05, 1.26 0.002
Excess alcohol consumption AND Falls Risk
Excess alcohol consumption [No] AND Falls Risk [Yes] 2.02 1.54, 2.63 <0.001
Excess alcohol consumption [Yes] AND Falls Risk [Yes] 7.62 2.77, 20.94 <0.001
Excess alcohol consumption AND Recurrent Falls
Excess alcohol consumption [NO] AND Recurrent Falls [YES] 2.03 1.48, 2.79 <0.001
Excess alcohol consumption [YES] AND Recurrent Falls [YES] 3.14 1.00, 9.80 0.049
Smoothed (PBF%) <0.001
Smoothed (Age) 0.714
Smoothed (Left Femoral Total T-score) <0.001
Smoothed (BMI) 0.450

Comparison between reporting 1 vs multiple fragility fractures. The reference category for binary variables was the absence of reporting the risk factor.

Excess alcohol consumption alone was not independently associated with increased odds of multiple fragility fractures (OR = 0.98, 95% CI: 0.83–1.14; p = 0.756). In contrast, current smoking was significantly associated with increased odds (OR = 1.27, 95% CI: 1.12–1.45; p < 0.001).

We identified significant interactions between alcohol consumption and both falls risk/recurrent falls in relation to reporting multiple fragility fractures. Amongst individuals who did not consume excess alcohol but were identified as a falls risk this was associated with higher odds of reporting multiple fragility fractures (OR 2.02, 95% CI: 1.54–2.63; p < 0.001). The odds increased markedly among those who both consumed excess alcohol and were identified as a falls risk (OR 7.62, 95% CI: 2.77–20.94; p < 0.001). A similar pattern was observed for recurrent falls: in non-drinkers, recurrent falls were associated with increased odds of multiple fractures (OR 2.03, 95% CI: 1.48–2.79; p < 0.001), an increased odds was also seen amongst those who drank excessively and reported recurrent falls (OR 3.14, 95% CI: 1.00–9.81; p = 0.049). These interaction effects are summarised in Table 2.

When examining continuous variables using smoothed terms, both the left femoral total T-score and PBF% demonstrated significant non-linear associations (estimated degrees of freedom [EDF] = 2.99 and 1.01 respectively; p < 0.001 for both) with the probability of reporting multiple fragility fractures. In contrast, the smoothed terms for age (p = 0.7) and BMI (p = 0.4) were not significantly associated with multiple fragility fractures.

The predicted probability of reporting multiple fragility fractures varied by T-score. A T-score of –4 was associated with a probability of approximately 22.5% to report multiple fragility fractures. This remained relatively flat until a T-score of –2, where the probability declined as bone density improved. This relationship is illustrated in Fig 1.

Fig 1. Marginal effects plot for the probability of reporting multiple vs a single fragility fracture based on the left femoral T-score while keeping all other variables in the model constant.

Fig 1

For PBF%, individuals with 20% PBF% had a predicted probability of approximately 17.5% for reporting multiple fragility fractures, compared to those with 60% PBF%, whose probability rose to approximately 27.5%. This positive association between increasing body fat and the probability of reporting multiple fragility fractures is shown in Fig 2.

Fig 2. Marginal effects plot for the probability of reporting multiple vs a single fragility fracture based on the PBF% while keeping all other variables in the model constant.

Fig 2

Discussion

To our knowledge, this study represents one of the largest clinical observational cohorts to date analysing patients with multiple fragility fractures, building upon the work of Charles et al. [9] and furthering the understanding of factors associated with multiple fragility fractures. We found that 20.8% of patients reported in our cohort reported multiple fragility fractures, which aligns with prior literature suggesting that 20–32% of patients will experience another fragility fracture within two years [8]. This highlights the high risk of experiencing multiple fragility fractures in at-risk populations, emphasizing the need for strategies to identify and treat these patients promptly.

We found that many traditional fractures risk factors were significantly associated with multiple fragility fractures. Interestingly, female gender, typically associated with an increased risk of fragility fractures, was associated with decreased odds in this study. This result should be interpreted with caution, as our sampling approach, which focused on a referred population, likely led to an overrepresentation of females. The males who were referred were generally older and more likely to report multiple fragility fractures, owing to the fact that men are generally less likely to be referred for DXA scans than females [16].

Rheumatoid arthritis was another key factor associated with multiple fragility fractures, increasing the odds by approximately 28% compared to those reporting only a single fragility fracture. Although we lacked access to disease markers, previous research has shown that disease activity markers, such as the Disease Activity Score 28 (DAS28), are associated with increased fracture risk [17]. This may be due to the accumulation of disability and joint deformity over time [18], increased falls risk in patients with rheumatoid arthritis [19] as well as the impact on bone density from both disease activity and glucocorticoid use. These findings highlight the importance of effective disease management and the need for clinicians to identify rheumatoid arthritis patients who may be at heightened risk of multiple fragility fractures.

Glucocorticoid therapy was also significantly associated with multiple fragility fractures, increasing the odds by approximately 22%. While the well-established effects of glucocorticoids on bone health are widely recognized [20], the impact on body composition may be overlooked. Glucocorticoid use can induce myopathy and Cushing’s syndrome, which is characterized by increased visceral adiposity and muscle wasting [21,22]. These changes can lead to instability and an increased risk of falls [23]. Therefore, while pharmacological treatment to improve bone density is crucial, a holistic approach that addresses compositional changes is also important. Research suggests that exercise may help prevent muscle loss, offering a potential strategy to mitigate the negative effects of glucocorticoid therapy [24].

What also stood out in our statistical analysis was the significant impact of modifiable risk factors on the risk of multiple fragility fractures. Notably, smoking was associated with a 28% increase in the odds of experiencing multiple fragility fractures. Furthermore, While excess alcohol consumption alone did not show a statistically significant association, we found a noteworthy interaction between alcohol consumption and fall risk. Specifically, patients at risk of falling who did not consume excess alcohol already had a 103% in the increase of odds in reporting multiple fragility fracture versus a single fracture. However, the odds were 683% higher when these patients consumed excess alcohol. This finding aligns with previous research showing that excessive alcohol consumption can impair stability and cognition, ultimately leading to falls especially in the elderly [25]. Hence, given the aging population and evidence suggesting that alcohol use is on the rise, possibly due to factors like social isolation, this is a novel relationship that is not well captured in current fracture risk calculators [26]. However, we acknowledge that the confidence intervals for these interactions were relatively wide indicating uncertainty, likely due to a small number of patients in individual groups. Consequently, larger samples are needed to ascertain the true effect size for drinking alcohol, being at a falls risk and subsequent fracture risk.

We acknowledge the potential criticism regarding the lack of clinical definitions for falls risk and recurrent falls predictors, albeit, this is a common problem in the literature at large [27]. However, we argue that even a clinical suspicion or family concern about a patient’s fall risk is sufficient to warrant further investigation. This should include exploring modifiable causes of falls and conducting a comprehensive clinical workup for osteoporosis to prevent fragility fractures. Furthermore, while falls are now starting to be included into FRAXplus [28] it may be wise for an interaction vs additive effect to be included in any risk algorithm to effectively capture this relationship. Hence, further research should explore the correlation between alcohol consumption, fall risk, and fracture risk prediction in prospective cohorts.

Ultimately, alcohol consumption remains a modifiable risk factor which interacts with falls risk to be associated with multiple fragility fractures. Our research suggests that interventions aimed at reducing excessive alcohol intake could be beneficial for patients at risk of multiple fragility fractures by ultimately preventing falls. These interventions may include self-help strategies or therapies such as cognitive-behavioural therapy, which has been shown to effectively reduce alcohol consumption [29]. Furthermore addressing underlying issues, such as social isolation and loneliness, is also crucial and is an ongoing area of research [30]. For patients with severe alcohol dependence, pharmacological treatments may be necessary to reduce alcohol intake however correlation to a reduction in falls risk has yet to be determined.

We also observed that bone density, as measured by the left femoral T-score, was significantly associated with multiple fragility fractures, with nonlinear effects noted. This emphasizes the important of bone density in protecting against multiple fractures [9]. While there are established indications for pharmacological therapies, such as romosozumab, in individuals at imminent risk of fracture, further research should explore the efficacy of these therapies in preventing multiple fragility fractures [31]. Additionally, markers of bone quality such as the trabecular bone score should be explored in relation to multiple fragility fractures, as a proportion of patients may present with normal bone density despite underlying skeletal fragility. Unfortunately, we did not have access to trabecular bone score data in our cohort. Another notable finding from our study is the potential value of body composition measurements as predictors of multiple fragility fractures.

Interestingly, we found that BMI was not significantly associated with reporting multiple fragility fractures. In contrast, our novel PBF% measurement was significantly linked to multiple fragility fractures, with nonlinear effects observed. This further supports the growing evidence that BMI may not be a reliable metric for inclusion in fracture risk calculators given the literature highlighting the importance of additional measures of body composition [32]. However, it is important to recognise that this is not a clinically validated body composition metric, but one derived based on data collected on a routinely collected DXA scan. Hence, we recommend that further research is needed to validate advanced composition model for inclusion in future fracture risk models.

BMI is relatively nonspecific and does not accurately account for the changes in body composition that occur in elderly and at-risk populations for fragility fractures [33]. Elderly patients often experience a reduction in muscle mass and an increase in fat, which research suggests can compromise stability and precipitate falls [34,35]. Our measurements of PBF% may be more sensitive to these changes, as they directly assess a component of compositional change, fat percentage [12]. While some may argue that measuring muscle mass may be more appropriate, much of the literature suggests that muscle mass is a relatively poor predictor of fragility fractures [36]. This further adds to the evidence supporting fat percentage as a predictor of fragility fractures.

Consequently, novel compositional variables should be considered for inclusion in fracture risk calculators, particularly for patients who have undergone DXA scans. There inclusion could enhance the accuracy and predictive capability of these calculators to predict multiple fragility fracture, facilitating earlier intervention. Furthermore, interventions aimed at improving body composition, such as aerobic exercise and resistance training, should be strongly recommended for this patient population to ensure adequate strength, control, and stability, thereby reducing the risk of multiple fragility fractures [37].

When considering our results in their totality, it may be argued that many of the associations identified in our model are already accounted for within FRAX. However, while FRAX is a useful and widely adopted tool, the dichotomisation of several key variables means changes would be needed to allow it to be useful in predicting multiple fragility fractures. Accounting for a spectrum of alcohol consumption levels [38], glucocorticoid therapy exposure [39], and the number of secondary causes of osteoporosis may improve the ability of fracture risk calculators to discriminate individuals at specific risk of sustaining multiple fragility fractures. Although FRAX values were not available for our cohort, it would also be of interest to assess how FRAX-predicted risk differs between individuals reporting a single versus multiple fragility fractures in a real-world population. This represents an important avenue for future research.

Strengths and limitations

The strengths of our study include the large sample size of patients with multiple fragility fractures and the comprehensive analysis of comorbidities and risk factors, which enhance the validity of our results. Our results are also strengthened as our patients had the gold standard of DXA for bone density.

However, our study has several limitations. Firstly, our population was predominantly Caucasian (95%+), which may not accurately reflect the broader UK population, although it is representative of the region where the scans were conducted. Additionally, the cross-sectional nature of our study (data collected only at the time of the first scan) limits our ability to draw causal conclusions. Given that our study involved a high-risk referred population, it may not reflect the general population and could be subject to sampling bias. We also acknowledge that recall bias when filling out the questionnaire may have influenced our findings, despite efforts to ensure data accuracy. Furthermore, the lack of specific dosage information for glucocorticoid therapy limits our ability to explore dose-dependent effects on fracture risk, which is crucial for understanding causality. Additionally, the lack of information on patients on antiresorptive represents another limitation as antiresorptive may modify the relationship between patients reporting versus not reporting multiple fragility fractures.

Conclusions

In conclusion, our study identifies several traditional risk factors for multiple fragility fractures, including family history of fragility fractures, rheumatoid arthritis, glucocorticoid use, smoking, and excessive alcohol consumption. Furthermore, we highlight a novel interaction effect between alcohol consumption, fall risk/recurrent falls in relation to multiple fragility fractures. Additionally, bone density and body composition, particularly PBF%, were found to significantly influence the risk of multiple fragility fractures. Further research is needed to allow accurate risk stratification of patients who will go on to experience multiple fragility fracture prior to any fragility fracture to facilitate timely intervention.

Data Availability

Data cannot be shared publicly because of patient confidentiality reasons. Data are available from the NHS trust Institutional Data Access (contact via the research support department: research.support@mbht.nhs.uk) for researchers who meet the criteria for access to confidential data.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6):368–81. doi: 10.1007/BF01622200 [DOI] [PubMed] [Google Scholar]
  • 2.Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–76. [DOI] [PubMed] [Google Scholar]
  • 3.Densitometry ISfC. 2019 ISCD Official Positions Adults 2019. Available from: https://iscd.org/learn/official-positions/adult-positions/ [Google Scholar]
  • 4.Rajan R, Cherian KE, Kapoor N, Paul TV. Trabecular Bone Score-An Emerging Tool in the Management of Osteoporosis. Indian J Endocrinol Metab. 2020;24(3):237–43. doi: 10.4103/ijem.IJEM_147_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Akkawi I, Zmerly H. Osteoporosis: Current Concepts. Joints. 2018;6(2):122–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Downey C, Kelly M, Quinlan JF. Changing trends in the mortality rate at 1-year post hip fracture - a systematic review. World J Orthop. 2019;10(3):166–75. doi: 10.5312/wjo.v10.i3.166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Society RO. ICS0035: Written evidence submitted Royal Osteoporosis Society. 2022. [Google Scholar]
  • 8.Söreskog E, Ström O, Spångéus A, Åkesson KE, Borgström F, Banefelt J, et al. Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone. 2020;134:115286. doi: 10.1016/j.bone.2020.115286 [DOI] [PubMed] [Google Scholar]
  • 9.Charles A, Iconaru L, Baleanu F, Benoit F, Surquin M, Mugisha A, et al. Are there specific clinical risk factors for the occurrence of multiple fractures? The FRISBEE study. Osteoporos Int. 2023;34(3):501–6. doi: 10.1007/s00198-022-06663-w [DOI] [PubMed] [Google Scholar]
  • 10.Zerikly R, Demetriou EW. Use of Fracture Risk Assessment Tool in clinical practice and Fracture Risk Assessment Tool future directions. Womens Health (Lond). 2024;20:17455057241231387. doi: 10.1177/17455057241231387 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kanis JA, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, et al. Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. Osteoporos Int. 2023;34(12):2027–45. doi: 10.1007/s00198-023-06870-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Amin H, Syed FA, Khan MA, Sultan Z, Bukhari M. Partial body fat percentage as a predictor of fragility fractures in a large cohort: a cross-sectional study. Rheumatol Adv Pract. 2024;8(1):rkae010. doi: 10.1093/rap/rkae010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Stults-Kolehmainen MA, Stanforth PR, Bartholomew JB, Lu T, Abolt CJ, Sinha R. DXA estimates of fat in abdominal, trunk and hip regions varies by ethnicity in men. Nutr Diabetes. 2013;3(3):e64. doi: 10.1038/nutd.2013.5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Santorelli G, West J, Yang T, Wright J, Bryant M, Lawlor DA. Differences in total and regional body fat and their association with BMI in UK-born White and South Asian children: findings from the Born in Bradford birth cohort. Wellcome Open Res. 2022;6:65. doi: 10.12688/wellcomeopenres.16659.3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tan GJ, Tan MP, Luben RN, Wareham NJ, Khaw K-T, Myint PK. The relationship between alcohol intake and falls hospitalization: Results from the EPIC-Norfolk. Geriatr Gerontol Int. 2021;21(8):657–63. doi: 10.1111/ggi.14219 [DOI] [PubMed] [Google Scholar]
  • 16.Frost M, Gudex C, Rubin KH, Brixen K, Abrahamsen B. Pattern of use of DXA scans in men: a cross-sectional, population-based study. Osteoporos Int. 2012;23(1):183–91. doi: 10.1007/s00198-011-1589-y [DOI] [PubMed] [Google Scholar]
  • 17.Ajeganova S, Andersson M, Forslind K, Gjertsson I, Nyhäll-Wåhlin B-M, Svensson B, et al. Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years. BMC Rheumatol. 2023;7(1):23. doi: 10.1186/s41927-023-00347-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Theander L, Sharma A, Karlsson MK, Åkesson KE, Jacobsson LTH, Turesson C. Risk and predictors of fractures in early rheumatoid arthritis - A long term follow up study of an inception cohort. Semin Arthritis Rheum. 2024;68:152497. doi: 10.1016/j.semarthrit.2024.152497 [DOI] [PubMed] [Google Scholar]
  • 19.Stanmore EK, Oldham J, Skelton DA, O’Neill T, Pilling M, Campbell AJ, et al. Risk factors for falls in adults with rheumatoid arthritis: a prospective study. Arthritis Care Res (Hoboken). 2013;65(8):1251–8. doi: 10.1002/acr.21987 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–65. doi: 10.1517/14740338.2016.1140743 [DOI] [PubMed] [Google Scholar]
  • 21.Lee M-J, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta. 2014;1842(3):473–81. doi: 10.1016/j.bbadis.2013.05.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Klein GL. THE EFFECT OF GLUCOCORTICOIDS ON BONE AND MUSCLE. Osteoporos Sarcopenia. 2015;1(1):39–45. doi: 10.1016/j.afos.2015.07.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zdrojowy-Wełna A, Stachowska B, Bolanowski M. Cushing’s disease and bone. Pituitary. 2024;27(6):837–46. doi: 10.1007/s11102-024-01427-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Macedo AG, Almeida TAF, Massini DA, De Paula VF, De Oliveira DM, Pessôa Filho DM. Effects of exercise training on glucocorticoid-induced muscle atrophy: Literature review. Steroids. 2023;195:109240. [DOI] [PubMed] [Google Scholar]
  • 25.Yuan K, Haddad Y, Law R, Shakya I, Haileyesus T, Navon L, et al. Emergency Department Visits for Alcohol-Associated Falls Among Older Adults in the United States, 2011 to 2020. Ann Emerg Med. 2023;82(6):666–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Breslow RA, Castle IP, Chen CM, Graubard BI. Trends in alcohol consumption among older Americans: National health interview surveys, 1997 to 2014. Alcohol Clin Exp Res. 2017;41(5):976–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jehu DA, Skelton DA. The measurement and reporting of falls: Recommendations for research and practice on defining faller types. J Frailty Sarcopenia Falls. 2023;8(4):200–3. doi: 10.22540/JFSF-08-200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Todorov G, Brook S, Quah Qin Xian N, Von Widekind S, Freudenthal B, Comninos AN. Comparison of fracture risk calculators in elderly fallers: a hospital-based cross-sectional study. BMJ Open. 2022;12(7):e060282. doi: 10.1136/bmjopen-2021-060282 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Magill M, Ray L, Kiluk B, Hoadley A, Bernstein M, Tonigan JS, et al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. J Consult Clin Psychol. 2019;87(12):1093–105. doi: 10.1037/ccp0000447 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Galvez-Hernandez P, González-de Paz L, Muntaner C. Primary care-based interventions addressing social isolation and loneliness in older people: a scoping review. BMJ Open. 2022;12(2):e057729. doi: 10.1136/bmjopen-2021-057729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Laura I, Felicia B, Alexia C, Aude M, Florence B, Murielle S, et al. Which treatment to prevent an imminent fracture?. Bone Rep. 2021;15:101105. doi: 10.1016/j.bonr.2021.101105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Chen R, Armamento-Villareal R. Obesity and Skeletal Fragility. J Clin Endocrinol Metab. 2024;109(2):e466–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Piñar-Gutierrez A, García-Fontana C, García-Fontana B, Muñoz-Torres M. Obesity and Bone Health: A Complex Relationship. Int J Mol Sci. 2022;23(15). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ponti F, Santoro A, Mercatelli D, Gasperini C, Conte M, Martucci M, et al. Aging and Imaging Assessment of Body Composition: From Fat to Facts. Front Endocrinol (Lausanne). 2020;10:861. doi: 10.3389/fendo.2019.00861 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Mitchell RJ, Lord SR, Harvey LA, Close JCT. Associations between obesity and overweight and fall risk, health status and quality of life in older people. Aust N Z J Public Health. 2014;38(1):13–8. doi: 10.1111/1753-6405.12152 [DOI] [PubMed] [Google Scholar]
  • 36.Vendrami C, Shevroja E, Gonzalez Rodriguez E, Gatineau G, Elmers J, Reginster J-Y, et al. Muscle parameters in fragility fracture risk prediction in older adults: A scoping review. J Cachexia Sarcopenia Muscle. 2024;15(2):477–500. doi: 10.1002/jcsm.13418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Sadaqa M, Németh Z, Makai A, Prémusz V, Hock M. Effectiveness of exercise interventions on fall prevention in ambulatory community-dwelling older adults: a systematic review with narrative synthesis. Front Public Health. 2023;11:1209319. doi: 10.3389/fpubh.2023.1209319 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ke Y, Hu H, Zhang J, Yuan L, Li T, Feng Y, et al. Alcohol Consumption and Risk of Fractures: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. Adv Nutr. 2023;14(4):599–611. doi: 10.1016/j.advnut.2023.03.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR. Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. J Bone Miner Res. 2018;33(10):1881–8. doi: 10.1002/jbmr.3523 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Gaetano Paride Arcidiacono

7 Jan 2026

Dear Dr. amin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Gaetano Paride Arcidiacono

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Competing Interests section:

“Disclosures:

HA declares no competing financial interests.

MAK declares no competing financial interests

MB has the following disclosures: M.B. has been sponsored to attend regional, national and international meetings by UCB Celltech, Roche/Chugai, Pfizer, Abbvie, Merck, Mennarini, Janssen, Bristol-Myers Squib, Novartis and Eli Lilly. He has received honoraria for speaking and attended advisory boards with Bristol-Myers Squib, UCB Celltech, Roche/Chugai, Pfizer, Abbvie, Merck, Mennarini, Sanofi-Aventis, Eli-Lilly, Janssen, Amgen, Novartis and Gilead. He has received honoraria from educational groups Revalidaid and TREG consultants.”

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

3. In the online submission form you indicate that your data is not available for proprietary reasons and have provided a contact point for accessing this data. Please note that your current contact point is a co-author on this manuscript. According to our Data Policy, the contact point must not be an author on the manuscript and must be an institutional contact, ideally not an individual. Please revise your data statement to a non-author institutional point of contact, such as a data access or ethics committee, and send this to us via return email. Please also include contact information for the third party organization, and please include the full citation of where the data can be found.

4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Reviewers' comments :

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: OVERALL ASSESSMENT: This is a methodologically sound observational study utilizing a large real-world DXA cohort (n=43,801) to identify predictors of multiple versus single fragility fractures. The GAM analysis is appropriate, confirming traditional risk factors while uncovering a novel alcohol-falls risk interaction (OR 7.60, 95% CI 2.77-20.9) with clear clinical implications. Particularly interesting is the potential role of PBF% as a novel body composition predictor. The study addresses an important gap, as literature specifically examining multiple fracture predictors remains limited.

REQUIRED MINOR REVISIONS: 1. ABSTRACT - BACKGROUND: Please add 1-2 sentences providing brief osteoporosis context, defining it as a chronic systemic disease characterized by reduced bone density, increased fragility fracture risk, and severe clinical consequences (morbidity, mortality, substantial healthcare costs).

2. METHODS - Data Collection: Remove hypothyroidism from the secondary osteoporosis causes list, as the literature does not consistently support it as a fracture risk factor. Indeed, I suggest to remove the patients with hypotyroidism from the secondary osteoporosis group.

3. DISCUSSION - Body Composition: Add a limitation statement clarifying that PBF% represents a partial measure (derived from lumbar spine + bilateral femurs only) rather than validated total body composition analysis. This warrants cautious interpretation of findings and prospective validation in future studies.

MINOR TECHNICAL POINTS

- Table 2: Please clarify the reference category for the alcohol × falls risk interaction terms

- Discussion: Consider briefly acknowledging that the cross-sectional design limits causal inferences

Reviewer #2: The authors have conducted a study addressing an important and clinically relevant question, namely the identification of predictors distinguishing single from multiple fragility fractures in a large observational cohort. The manuscript is generally clear, methodologically sound, and the conclusions are largely supported by the presented data. I believe the study is suitable for publication after minor revisions.

- Introduction. The authors state that osteoporosis is defined by the World Health Organization (WHO) as a reduction in bone density of 2.5 standard deviations below that of a young healthy adult population, measured at the femoral neck. This definition could be reformulated to better reflect the original WHO reference by incorporating both microarchitectural alterations and a more precise densitometric description.

- Results. It may be appropriate to include a study flow chart as the first figure in the Results section to clearly illustrate the number of subjects initially screened and those ultimately included in the final analysis.

- Results. Many of the predictors of multiple fragility fractures identified in this study are already included in FRAX or FRAXplus, which represent established tools for the simultaneous integration of multiple clinical risk factors. It would therefore be of interest to assess whether differences in estimated fracture probability exist between individuals reporting a single versus multiple fragility fractures, and whether a specific probability threshold could be identified to discriminate between these two groups.

- Results. The manuscript does not include information on osteoporosis-specific treatments (e.g. antiresorptive or anabolic therapies), which may substantially influence fracture risk and the occurrence of multiple fragility fractures. The authors should clarify whether treatment data were unavailable or not collected, and acknowledge this as a limitation, as prior or ongoing therapy could confound the observed associations.

- Results. The very high odds ratio observed for the interaction between excessive alcohol consumption and falls risk may be influenced by the relatively small number of individuals in this subgroup. This is also reflected by the wide confidence intervals. The authors are encouraged to acknowledge this limitation explicitly in the Results or Discussion

- General comment. For consistency and clarity, all p-values should be reported to three decimal places throughout the text and tables. When p-values are smaller than this threshold, they should be reported uniformly as p<0.001.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

Decision Letter 1

Gaetano Paride Arcidiacono

5 Feb 2026

Investigating traditional and novel predictors of a single versus multiple fragility fractures in a large observational cohort

PONE-D-25-39019R1

Dear Dr. amin,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gaetano Paride Arcidiacono

Academic Editor

PLOS One

Acceptance letter

Gaetano Paride Arcidiacono

PONE-D-25-39019R1

PLOS One

Dear Dr. amin,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Gaetano Paride Arcidiacono

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: rebuttal letter .docx

    pone.0343413.s001.docx (25KB, docx)

    Data Availability Statement

    Data cannot be shared publicly because of patient confidentiality reasons. Data are available from the NHS trust Institutional Data Access (contact via the research support department: research.support@mbht.nhs.uk) for researchers who meet the criteria for access to confidential data.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES